Categories Consumer, Earnings, Retail

Earnings preview: How will Q2 turn out for Kroger?

The Kroger Co. (NYSE: KR) is slated to report second quarter 2019 earnings results on Thursday, September 12, before the market opens. Analysts expect the company to report earnings of $0.41 per share on revenue of $28.38 billion.

The retail sector is seeing heavy competition with major players investing heavily in improving their delivery services and omni-channel capabilities. This is particularly visible in the grocery space where companies like Kroger have introduced several new initiatives to drive traffic and sales. The Restock Kroger program, along with other investments, are likely to benefit the second quarter results.

Kroger first quarter 2019 earnings snapshot

Kroger has also expanded its assortment with the launch of Simple Truth Plant-Based food products. The acquisitions of Ocado, Home Chef, and Nuro will also help in improving the company’s capabilities and driving growth. However, higher costs are likely to weigh on margins in the to-be-reported quarter.

In the first quarter of 2019, Kroger missed revenue estimates while earnings matched expectations. Sales dipped 1.2% to $37.2 billion while adjusted EPS declined 1.4% to $0.72. The topline numbers were impacted by the sale of Kroger’s convenience store business unit. Identical sales, excluding fuel, increased 1.5%.

Also see: Kroger Q1 2019 Earnings Conference Call Transcript

For fiscal 2019, Kroger expects GAAP EPS to be $2.38 to $2.48 and adjusted EPS to be $2.15 to $2.25. Identical sales growth, excluding fuel, is predicted to be in the range of 2% to 2.25%. Kroger’s financial strategy is to use its free cash flow to drive growth while maintaining its current investment grade debt rating and returning capital to shareholders. 

Kroger’s shares have gained 4% in the past three months and 7% in the past one month. The stock was up 1.5% during afternoon hours on Monday.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top